122 related articles for article (PubMed ID: 36702131)
21. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
[TBL] [Abstract][Full Text] [Related]
23. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test.
Tsuji Y; Gunji T; Sato H; Ono A; Ito T; Ohata K; Yamamichi N; Fujishiro M; Matsuhashi N; Koike K
Dig Endosc; 2014 May; 26(3):424-9. PubMed ID: 24325675
[TBL] [Abstract][Full Text] [Related]
25. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
[TBL] [Abstract][Full Text] [Related]
26. Optimizing Screening for Colorectal Cancer: An Algorithm Combining Fecal Immunochemical Test, Blood-Based Cancer-Associated Proteins and Demographics to Reduce Colonoscopy Burden.
Petersen MM; Kleif J; Jørgensen LN; Hendel JW; Seidelin JB; Madsen MR; Vilandt J; Brandsborg S; Rasmussen JS; Andersen LM; Khalid A; Ferm L; Gawel SH; Martens F; Andersen B; Rasmussen M; Davis GJ; Christensen IJ; Therkildsen C
Clin Colorectal Cancer; 2023 Jun; 22(2):199-210. PubMed ID: 36878807
[TBL] [Abstract][Full Text] [Related]
27. Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.
Shahidi N; Gentile L; Gondara L; Hamm J; McGahan CE; Enns R; Telford J
Can J Gastroenterol Hepatol; 2016; 2016():4650471. PubMed ID: 28116286
[No Abstract] [Full Text] [Related]
28. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
29. Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
Law J; Rajan A; Trieu H; Azizian J; Berry R; Beaven SW; Tabibian JH
Dig Dis Sci; 2022 Jul; 67(7):2842-2848. PubMed ID: 34350518
[TBL] [Abstract][Full Text] [Related]
30. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
[TBL] [Abstract][Full Text] [Related]
31. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
[No Abstract] [Full Text] [Related]
32. Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.
Elangovan A; Skeans J; Lalani I; Ullah F; Roy A; Kaelber DC; Cooper GS; Sandhu DS
Dig Dis Sci; 2021 Aug; 66(8):2585-2594. PubMed ID: 32816217
[TBL] [Abstract][Full Text] [Related]
33. Effects of antithrombotic drugs on the results of fecal immunochemical test in colorectal neoplasms screening.
Ibuka T; Adachi S; Horibe Y; Ohno T; Mabuchi M; Suzuki Y; Yamauchi O; Takada E; Iwama M; Saito K; Arao M; Takai K; Araki H; Shimizu M
Sci Rep; 2021 Feb; 11(1):4348. PubMed ID: 33623065
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
[TBL] [Abstract][Full Text] [Related]
35. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
36. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
[TBL] [Abstract][Full Text] [Related]
37. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with adherence to colonoscopy among individuals who were positive in the preliminary screening for colorectal neoplasms.
Li JB; Ke KJ; Zhang WL; Wang LY; Wu YP; Weng F; Tian H; Qiu ZY; Li Y; Lin SY; Ye MX; Ou QJ; Gong CH; Lu ZH; Pan ZZ; Wan DS; Peng JH; Fang YJ
Cancer Med; 2022 Nov; 11(22):4321-4331. PubMed ID: 35441812
[TBL] [Abstract][Full Text] [Related]
39. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
40. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial.
Randel KR; Schult AL; Botteri E; Hoff G; Bretthauer M; Ursin G; Natvig E; Berstad P; Jørgensen A; Sandvei PK; Olsen ME; Frigstad SO; Darre-Næss O; Norvard ER; Bolstad N; Kørner H; Wibe A; Wensaas KA; de Lange T; Holme Ø
Gastroenterology; 2021 Mar; 160(4):1085-1096.e5. PubMed ID: 33227280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
